Hetlioz is approved to treat the rare disease non-24-hour sleep-wake disorder, a circadian rhythm problem that crops up primarily in blind people. This is the third letter sent this month, a notable increase over the 2018 pace till now. Before October, the OPDP had only sent four letters. The newest round brings the year's total to seven, already two ahead of last year's total, with two more months to go.